Outcome of a hospital based multidisciplinary weight loss program in obese Filipino children

Ann Marie Tan-Ting1, Luisito Llido1

  • 1Obesity and Weight Management Center, St. Luke's Medical Center, Quezon City, Metro-Manila, Philippines.

Insights

A 3-month multidisciplinary weight loss program effectively reduced weight, BMI, and body fat in obese Filipino children. Greater attendance at program sessions correlated with more significant weight loss results.

Area of Science:

  • Pediatrics
  • Public Health
  • Obesity Research

Background:

  • Childhood obesity is a growing concern in the Philippines, with increasing national prevalence.
  • A multidisciplinary approach integrating diet, exercise, and behavioral therapy is recommended for pediatric weight management.

Purpose of the Study:

  • To evaluate the effectiveness of a staged, 3-month multidisciplinary intervention for obese children.
  • The intervention combined dietary changes, physical activity, and behavioral strategies.

Main Methods:

  • A prospective study was conducted at a hospital-based weight management center over 15 months.
  • Participants included 44 obese children (aged 5-17 years) with BMI between the 85th-99th percentile.
  • Outcome measures included changes in weight, BMI, BMI z-score, body fat, blood pressure, and waist circumference.

Main Results:

  • The program led to significant reductions in weight (mean 4.2 kg, 5.3%), BMI (1.5 units), BMI z-score (0.15), body fat (14%), systolic blood pressure (7.25 mm Hg), and waist circumference (5.4 cm).
  • Weight loss, BMI reduction, and body fat decrease were significantly correlated with the number of program sessions attended.

Conclusions:

  • A 3-month staged, multidisciplinary program is effective for weight loss in obese Filipino children.
  • The frequency of session attendance positively influenced the degree of weight loss achieved.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...